Zhenzhen Li, Ning Sun, Xianghua Liu
The Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China,
Tumour Biol. 2014 Jan;35(1):433-40. doi: 10.1007/s13277-013-1060-0. Epub 2013 Aug 28.
To data, epidemiological studies have assessed the association between peptidyl-propyl-cis/trans isomerase 1 (PIN1) gene polymorphisms and cancer risk, including breast cancer, hepatocellular carcinoma, lung cancer, esophageal cancer, head and neck squamous cell carcinoma, and laryngeal squamous cell cancer. However, the results of these studies remain controversial. We aimed to examine the associations between two SNPs (rs2233678 and rs2233679) of PIN1 gene and cancer risk by conducting a meta-analysis of case-control studies. A total of seven publications were included in this meta-analysis for both rs2233678 and rs2233679. Overall, rs2233678 polymorphism was found to be associated with decreased cancer risk in four genetic models (C-allele vs. G-allele: odd ratio (OR) = 0.73, 95% confidence interval (CI): 0.60-0.88; CC vs. GG: OR = 0.55, 95% CI: 0.36-0.84; CC+CG vs. GG: OR = 0.72, 95% CI 0.58-0.90; CC vs. CG+GG: OR = 0.58, 95% CI 0.38-0.89). However, the rs2233679 polymorphism of PIN1 gene did not appear to have an influence on caner susceptibility. In the subgroup analysis by cancer type, we observed that the PIN1 rs2233678 polymorphism was significantly associated with decreased breast cancer risk (C-allele vs. G-allele: OR = 0.73, 95% CI: 0.60-0.89; CC+CG vs. GG: OR = 0.71, 95% CI 0.57-0.89). Further subgroup analyses showed that the PIN1 rs2233678 polymorphism was associated with decreased cancer risk among Asian people (C-allele vs. G-allele: OR = 0.63, 95% CI: 0.51-0.79; CC vs. GG: OR = 0.44, 95% CI: 0.25-0.80; CC+CG vs. GG: OR = 0.63, 95% CI 0.50-0.79; CC vs. CG+GG: OR = 0.47, 95% CI 0.26-0.86). In conclusion, PIN1 rs2233678 polymorphism might be a potential biomarker for cancer risk among Asians, especially for breast cancer. Further large and well-designed studies are needed to confirm this conclusion.
迄今为止，流行病学研究已评估了肽基脯氨酰顺/反异构酶1（PIN1）基因多态性与癌症风险之间的关联，这些癌症包括乳腺癌、肝细胞癌、肺癌、食管癌、头颈部鳞状细胞癌和喉鳞状细胞癌。然而，这些研究结果仍存在争议。我们旨在通过对病例对照研究进行荟萃分析，来检验PIN1基因的两个单核苷酸多态性（SNP，rs2233678和rs2233679）与癌症风险之间的关联。本荟萃分析共纳入了7篇关于rs2233678和rs2233679的出版物。总体而言，在四种遗传模型中发现rs2233678多态性与癌症风险降低相关（C等位基因与G等位基因：比值比（OR）=0.73，95%置信区间（CI）：0.60-0.88；CC与GG：OR=0.55，95%CI：0.36-0.84；CC+CG与GG：OR=0.72，95%CI ：0.58-0.90；CC与CG+GG：OR=0.58，95%CI ：0.38-0.89）。然而，PIN1基因的rs2233679多态性似乎对癌症易感性没有影响。在按癌症类型进行的亚组分析中，我们观察到PIN1 rs2233678多态性与乳腺癌风险降低显著相关（C等位基因与G等位基因：OR=0.73，95%CI：0.60-0.89；CC+CG与GG：OR=0.71，95%CI ：0.57-0.89）。进一步的亚组分析表明，PIN1 rs2233678多态性与亚洲人群癌症风险降低相关（C等位基因与G等位基因：OR=0.63，95%CI：0.51-0.79；CC与GG：OR=0.44，95%CI：0.25-0.80；CC+CG与GG：OR=0.63，95%CI ：0.50-0.79；CC与CG+GG：OR=0.47，95%CI ：0.26-0.86）。总之，PIN1 rs2233678多态性可能是亚洲人群癌症风险的潜在生物标志物，尤其是对于乳腺癌。需要进一步开展大规模且设计良好的研究来证实这一结论。
